Alpha Cognition Inc (ACOG)vsEli Lilly and Company (LLY)
ACOG
Alpha Cognition Inc
$5.87
-5.32%
HEALTHCARE · Cap: $127.81M
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 637641% more annual revenue ($65.18B vs $10.22M). LLY leads profitability with a 31.7% profit margin vs -202.2%. LLY earns a higher WallStSmart Score of 78/100 (B+).
ACOG
Avoid22
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -40.7% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : ACOG
The primary concerns for ACOG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ACOG profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.52 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 22/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is an innovative biopharmaceutical firm focused on developing advanced therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its flagship product, ACOG-100, aims to improve cognitive function and fulfill critical unmet medical needs among the aging population. Leveraging a proprietary neuroscience platform and a comprehensive R&D strategy, the company is poised to make significant strides in patient care. As Alpha Cognition progresses with its clinical pipeline and explores new therapeutic options, it presents an appealing investment opportunity for institutional investors seeking to engage with the transformative healthcare sector.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?